When rat mast cells sensitized by IgE antibody were exposed to antigen, transmission elec tron microscopy revealed alteration of the granules, cavity formation by fusion of the perigranular mem brane and granule release by the fusion of the cavity membrane with the mast cell membrane. Scanning elec tron microscopy disclosed the extrusion of smooth and round bodies from pores formed on the cell surface. These changes were accompanied by the release of histamine. The inhibition of this degranulation by a novel anti-allergic agent, 6-(1-pyrrolidinyl)-N-(1H-tetrazol-5-yl)-2-pyrazinecarboxamide (PTPC), was evalu ated quantitatively as an inhibition of the granule alteration and cavity formation. At a concentration of 100 nM, PTPC inhibited the granule alteration and cavity formation as well as histamine release. In the same concentration, PTPC significantly increased the cyclic AMP content in the mast cells. These results sug gest that the inhibition of the morphological changes in mast cells by PTPC might be due to the increased cyclic AMP caused by the agent and plays an important role in the suppression of chemical mediators re lease.
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Keywords: Mast cell degranulation (rat), Anti-allergic agent, PTPC, Granule alteration, Cyclic AMP Mast cell and basophil degranulation plays an im portant role in the immediate hypersensitivity reaction mediated by IgE antibody. It is well known that IgE molecules bind with high affinity to the Fc receptors on these cells (1, 2) . The bridging of the cell-bound IgE molecules with multivalent ligand initiates a cascade of biochemical events (3) resulting in the release of a variety of preformed and newly generated chemical mediators (4) . The morphology of the mast cell degranulation has been studied extensively, and exocytosis is accepted as the degranulation mechanism in rat mast cells. However, most of the in vitro studies (5) (6) (7) were performed by us ing secretagogues, and some differences exist among these degranulation stimuli (8, 9) . In our previous report, we have described the biochemical and morphological mecha nisms involved in mast cell degranulation in an IgE mediated cell model and the evaluation of the pharma cological properties of anti-allergic agents in type I allergy (10) .
In the present experiments, degranulation of IgE-sen sitized rat mast cells induced by the specific antigen was further studied using electron microscopy. The ultra-struc tural changes in isolated peritoneal mast cells were exam ined quantitatively, and the inhibitory effects of the hista mine release inhibitor, PTPC {6-(1-pyrrolidinyl)-N-(1H tetrazol-5-yl)-2-pyrazinecarboxamide}, on degranulation were determined. PTPC is an orally active and a potent inhibitor of passive cutaneous anaphylaxis (PCA) in rats and inhibits histamine release from mast cells (11), but its inhibitory mechanism is unknown.
MATERIALS AND METHODS

Chemicals
PTPC, 6-(1-pyrrolidinyl)-N-(1H-tetrazol-5-yl)-2-pyr azinecarboxamide, was synthesized by Hokuriku Seiyaku Co., Katsuyama. The following compounds were pur chased: bovine serum albumin (BSA) and (±)-isoproter enol hydrochloride (isoproterenol) from Sigma Chemical Co., St. Louis, MO, USA; sodium 2,4-dinitrophenyl sul fate from Tokyo Kasei Co., Tokyo; Bordetella pertussis vaccine from Kaken Seiyaku Co., Tokyo; trichloroacetic acid from Wako Pure Chemical Industries, Osaka; and Percoll from Pharmacia Fine Chemicals, Uppsala, Sweden.
Preparation of mast cells
Male Wistar rats weighing 350-450 g were sacrificed by decapitation under diethylether anesthesia and injected i.p. with 15 ml of ice-cold Hepes buffer containing 137 mM NaCl, 2.7 mM KC1, 1.0 mM Na2HPO4, 1.0 MM CaC12, 5.6 mM glucose, 10.0 mM 4-(2-hydroxyethyl)-1 piperazine ethanesulphonic acid (Hepes), 10 units/ml heparin and 3 mg/ml BSA (12) . The abdomen was gently massaged for 2 min; and the peritoneal lavage was collect ed, centrifuged at 30 x g for 5 min, and the mast cells were then separated from the other peritoneal cells by the method of Nemeth and Rohlich (13) . The purity of mast cells in the suspension was above 95°7o, and the viability was above 98% as assessed by trypan blue extrusion. This study complied with the animal welfare regulations of Tokyo Medical and Dental University.
Preparation of antiserum
Antiserum containing homocytotropic antibody, IgE, was prepared in rats sensitized by dinitrophenylated Ascaris extracts (DNP-As) mixed with 1010 Bordetella pertussis as described by Tada and Okumura (14) . The titer of antiserum was estimated to be 1 : 2048.
Passive sensitization of mast cells
Purified mast cells were incubated with appropriately diluted antiserum for 2 hr at 37C, washed with ice-cold Hepes buffer and centrifuged at 30 x g for 5 min to re move excess antiserum.
Assay of histamine
The IgE-sensitized mast cells were divided into six ali quots each containing 105 cells per 0.4 ml of Hepes buffer. The six aliquots were divided into three pairs. The first two aliquots were used for the spontaneous release without any treatment, and the second pair served as con trols incubated with antigen (DNP-As, with a final concen tration of 20 ug/ml in Hepes buffer). The third pair was pretreated for 1 min with PTPC (final concentration of 100 nM) followed by an incubation with the antigen. PTPC was dissolved in 0.1 N NaOH, neutralized with 0.1 N HCl and diluted by the distilled water. After prewarming the tubes at 37C for 10 min under gentle shaking, the antigen-antibody reaction was started. After a further 2-min incubation, the reaction was terminated by adding 1 ml of ice-cold Hepes buffer. After centrifuga tion, histamine in the supernatants and cell precipitates were assayed fluorometrically according to Shore et al. (15) . The percentage of histamine released was calculated as {A/(A+B)} x 100, where A was the amount of histamine in the supernatant and B, the amount in the precipitate. The inhibition ratio of histamine release by PTPC was cal culated as { 1 (E C)/(D C) } x 100, where C was the percentage of spontaneous histamine release, D, the per centage due to antigen and E, the percentage due to PTPC + antigen. In the preliminary experiment, the effect of PTPC on the IgE-mediated histamine release was deter mined at three different concentrations (10, 100 and 1,000 nM) according to the method described above.
Scanning (SEM) and transmission electron microscopy (TEM)
The IgE-sensitized mast cells were divided into three aliquots containing 106 cells per 0.4 ml Hepes buffer. The antigen-antibody reaction was performed by the method described above. The cell precipitates were fixed with 0.1 M cacodylate-buffered paraformaldehyde-glutaraldehyde solution, pH 7.4, for 2 hr at room temperature and washed three times with 0.1 M cacodylate buffer. The cell precipitates were then treated with 0.1 M cacodylate buffered osmium tetroxide solution for 2 hr at 4C. After post-fixation, the cells were washed and resuspended with 0.1 M cacodylate buffer. One drop of the fixed cell suspen sion was put on a filter paper, dehydrated in an ascending series of ethanols, processed through isoamyl acetate, critical-point-dried by carbon dioxide, coated with gold and examined under a scanning electron microscope (CSM-501; Comtec, Tokyo). For TEM, the fixed cell precipitates in small cubes of agar were dehydrated in an ascending series of ethanols and embedded in epoxy resin according to the method of Luft (16) . Ultrathin sections from randomly selected blocks were cut on an ultratome (MT2-B; DuPont, Newtown, CT, USA), doubly stained with uranyl acetate and lead citrate and examined by an electron microscope (H-300S; Hitachi, Tokyo). About 100 mast cells from each treatment were photographed at a magnification of x 6,000 for the quantitative evaluation of mast cell degranulation. The inhibition ratios of the morphological changes by PTPC were calculated in the same way as the inhibition ratio of the histamine release.
Assay of cyclic AMP
The purified mast cells (2 x 105 cells/ml) were divided into two aliquots containing 0.8 ml of Hepes buffer. After prewarming the tubes at 371C for 10 min, each tube was in cubated with 0.2 ml of Hepes buffer or PTPC (final con centration of 100 nM), respectively. After 1 min, the reac tion was stopped by the addition of 1 ml of 8% trichloro acetic acid (TCA) and stored frozen in liquid nitrogen. The thawed mixture was centrifuged at 1,200 x g for 10 min, and the precipitates were again extracted with 0.8 ml of 8% TCA. The TCA in the combined supernatant fluid was removed by extracting 5 times with water-saturated ether, and the aqueous layer was lyophilized. The residue was dissolved in 0.1 ml of 10 mM Tris buffer (pH 7.5), and the quantity of cyclic AMP was determined by a radioimmunoassay, using a commercial kit (Yamasa, Chiba).
Statistical analyses
Data are presented as the mean±S.E. and analyzed by Student's t-test, the Mann-Whitney U-test or X2-test. A probability <0.05 was considered significant. 
RESULTS
Histamine release
In the preliminary experiment, PTPC exhibited a con centration-dependent inhibition of the IgE-mediated histamine release from purified mast cells (percent inhibi tion: 18.8±3.5% at 10 nM (n=4), 73.1 ±8.8% at 100 nM (n=4) and 85.2±6.5% at 1,000 nM (n=4)). Therefore, 100 nM of PTPC, which would produce a sufficient inhibi tion while keeping sufficient specificity, was selected in the present experiment. As shown in Table 1 , the sponta neous histamine release in the control suspension was 2.9--1-0.7076 (n=5); and with the antigen (DNP-As) challenge, it was 16.1±2.907o from mast cells sensitized passively with the IgE antibody. The IgE antibody-mediat ed histamine release was significantly inhibited by PTPC (100 nM), as shown by the inhibition ratio of 83.2%. Fur thermore, PTPC (100 nM) did not interfere with the assay of histamine (data not shown).
Fig. 5.
Scanning electron micrograph of an IgE-sensitized rat peritoneal mast cell before antigen challenge.
The mast cell was globular, and its surface was covered by many ridges and a few microvilli. x 8,000.
Degranulation of peritoneal mast cells incubated with an tigen TEM examination: The mast cells sensitized passively with the IgE antibody were round to oval and 7 to 13 ,um in diameter. Cells had uniformly distributed surface processes and electron-dense, round or oval about 1 pm in diameter granules that were densely packed in the cytoplasm (Fig. 1) . A few granules of lower electron-den sity, corresponding to the so-called altered granules described by Bloom and Haegermark (17) , were also often found even in intact mast cells.
Ultrastructural changes in the mast cells could be ob served 2 min after incubation with antigen (Fig. 2, a and  b ). Some granules had decreased electron-density and others were present outside the cell membranes. The gran ules could be classified into three types. Type I granules were electron-dense and homogeneous (Fig. 3a) . Type II granules were slightly swollen and had lower electron-den sity with a fine granule matrix and a space between the matrix and the perigranular membrane (Fig. 3b ). Type III granules were more swollen and were less dense than type II granules (Fig. 3c ). Transitional forms between types II and III granules were occasionally found. The altered granules reported in the literature were identical with types II and III granules. Beneath the cell membrane, the perigranular membranes of adjacent altered granules were fused (Fig. 4a ) and formed larger cavities (Fig. 4b) .
The membranes surrounding these cavities were fused with the plasma membrane releasing altered granules from the cavity and from the cytoplasm (Fig. 4c ). Perigranular membranes of granules just beneath the cell surface directly fused with plasma membranes, indicated imminent discharge outside the cells. The degree of gran ule release varied in different cells, occurring at either one or two points ( Fig. 2a) or over the entire cell surface (Fig.  2b) . The altered granules and the fusion of perigranular membranes were occasionally also found deeper in the cytoplasm.
SEM examination: The mast cells were generally globu lar, and the entire visible surface of each cell was covered with low round elevations, presumably due to the presence of granules just beneath the cell membrane. There were also irregularly distributed membranous ridges and microvilli on the cell surface ( Fig. 5 ). In the mast cells exposed to antigen, pores between 0.6 and 0.8 ,um in diameter were found on the cell surface and smooth round bodies, probably granules of about 0.6 ,um in diameter, were observed within the pores and on the cell surface near the pores (Fig. 6 ). Some mast cells ex posed to antigen had larger pores, from which the extru sion of many bodies could be seen (Fig. 7) . In the cells not exposed to antigen or pretreated with PTPC, pores and as sociated smooth round bodies were rarely observed.
Quantitative evaluation by TEM of mast cell degranula tion
Each section of mast cell contained about one hundred granules, and the ratio of type II and type III granules increased significantly in the samples challenged with antigen. The incidence of mast cells with cavities also increased in the samples challenged with antigen. These changes were, however, inhibited by pretreatment with PTPC (100 nM) ( Fig. 8 and Table 2 ), and the inhibition ratio of an increase in type III granules was 91.2%.
Cyclic AMP content
When purified mast cells were incubated with PTPC (100 nM) for 1 min, the cyclic AMP content was in creased by 1.9-fold (P<0.01) over that of the control (Table 3 ). For the purpose of amplifying this increase, iso proterenol, which known to produce the cyclic AMP by adenylate cyclase activation, was used together with PTPC. When mast cells were incubated with PTPC in combination with isoproterenol (final concentration of 100 nM, respectively), the cyclic AMP content was syner gistically increased by 140-fold. Furthermore, neither PTPC nor isoproterenol interfered with the assay of cyclic AMP (data not shown). 
Degranulation of mast cells after antigen challenge.
A larger pore through which smooth round bodies extruded was
formed.
x 4,000. 
DISCUSSION
The process of mast cell degranulation by exocytosis has been studied in detail in rat peritoneal mast cells stimu lated by compound 48/80 (5) . The authors demonstrated that granules situated near the periphery of the cell were the first to be promptly extruded. Granules lying deeper within the cell were then extruded into the resulting cav ity. This process was repeated, resulting in a series of inter connected cavities, and thus directly communicating with the extracellular space. Anderson et al. (18) using TEM observed that sequential exocytosis of histamine-storing granules takes place when sensitized rat peritoneal mast cells are incubated with antigen. Tizard and Holmes (19) studied degranulation of rat peritoneal mast cells by SEM following chemical treatment and exposure to a specific antigen. They concluded that both exocytosis and pore formation on the cell surface were important mechanisms for degranulation, and there were no morphological differences between changes induced either by chemicals or by antigen. However, it has been reported that com pound 48/80 initiates histamine release through a bio chemical mechanism different from that observed in the IgE-mediated reaction (20, 21) . Moreover, PTPC was without effect on the histamine release induced by A23187 or compound 48/80 (at a higher concentration of 1 pg/ml), although PTPC inhibited the histamine release induced by the lower concentration of compound 48/80 (0.1 pg/ml) or by antigen (11) . Antigen challenge resulted in an initial increase in al tered granules and fusion of perigranular membranes. Subsequently, the membrane surrounding the cavity con taining altered granules fused with the cell surface. Final ly, discharge of altered granules into the extracellular space was observed. The cytoplasmic granules could be classified into three types. Type I granules, which were usually seen in the cells of control samples, had the most electron-dense matrices, presumably containing preform ed mediators. Type II and III granules had less electron dense matrices and were distinguished from each other by the fine structure of their granular matrices. From the differences in incidence of granule types and the increased occurrence of type III granules in the extracellular sur roundings, it was concluded that binding of IgE mole cules with antigen transformed type I into type II and subsequently into type III granules. During the alteration of these granules, sequential biochemical events prob ably occur in their matrices, following which preformed mediators such as histamine might be released and media tors such as peptide-leukotriene might be synthesized.
Pretreatment with PTPC (100 nM) significantly inhibit ed histamine release. It was also found that the number of altered granules and the number of cells with cavities sig nificantly decreased after pretreatment with the agent. Similar results were reported with tranilast (100 t_iM) (10); however, PTPC was more potent.
It is widely accepted that cyclic AMP plays a role as a second messenger to inhibit histamine release from mast cells (22) . The increase in cyclic AMP content caused by PTPC correlated with its inhibitory effect on the IgE mediated histamine release. Makino et al. (23) have reported that amlexanox, an anti-allergic agent, inhibited the histamine release by increasing the cyclic AMP con tent in mast cells. They also proposed that increase of cyclic AMP was caused by enhancing the cyclic AMP synthesis in addition to inhibiting cyclic AMP phospho diesterase. Yamada et al. (24) reported that MY-1250, an active metabolite of repirinast, induced phosphoryla tion of a 78-kDa protein in rat mast cells through a cyclic AMP-dependent mechanism (25) . They also suggested that the phosphorylation of the substrate protein was involved in the termination or limitation of the histamine release, and that anti-allergic agents commonly exerted their anti-secretory activity by inducing phosphorylation of this protein.
Therefore, all findings described lead us to speculate that the increased cyclic AMP with PTPC mediates phos phorylation of the substrate protein and, in turn, brings about the inhibition of morphological changes in mast cells. This may play an important role in the suppression of chemical mediator release. The precise inhibition mechanism by PTPC, however, remains to be investigat ed, including its effect on the IgE-mediated histamine re lease and its effect on the morphological changes in mast cells when cells were incubated with PTPC in combina tion with isoproterenol, under which condition the cyclic AMP content was synergistically increased. Table 2 .
Morphological changes of IgE-sensitized rat peritoneal mast cells induced by antigen and their inhibition with PTPC Table 3 . Effect of PTPC on cyclic AMP content in rat mast cells
